ImmuPharma PLC (AIM:IMM, OTC:IMMPF) plans to focus this year on advancing Lupuzor, its lupus treatment, into phase II/III clinical trials later in the year.
The company’s progression towards critical testing in the latter half of the year might align with the initial clinical evaluation of the drug in patients suffering from the chronic neurological condition, chronic idiopathic demyelinating polyneuropathy (CIDP), according to the information given to investors.
The company’s full-year results included this update, also recapping the significant progress ImmuPharma has made so far. This includes a successful pharmacokinetic study of Lupuzor and the establishment of an adaptive trial with US regulators for the medication.
There are two more scheduled meetings with the Food and Drug Administration (FDA) in May and June, to discuss the specific protocols for the upcoming CIDP and lupus studies respectively.
As expected, due to its investment in R&D and preparatory work for the upcoming clinical trials, ImmuPharma reported a loss for the year ending 31 December 2022. The loss amounted to £3.8mln, with the company ending the period with a cash balance of £700,000.
